Integration of anticoagulation, thrombolysis and coronary angioplasty for unstable angina pectoris

Area of Science:

• Cardiology
• Vascular Medicine
• Acute Ischemic Syndromes

Background:

• Unstable angina pectoris is a challenging acute ischemic syndrome.
• Intravenous heparin is beneficial, but angioplasty is complicated by thrombus, increasing abrupt closure risk.
• Thrombolytic therapy has yielded equivocal results in treating unstable angina.

Purpose of the Study:

• To review current recommendations for integrating heparin, thrombolysis, and coronary angioplasty for unstable angina pectoris.
• To assess the impact of heparin pretreatment on angioplasty outcomes.
• To evaluate the efficacy of thrombolytic therapy in conjunction with angioplasty.

Main Methods:

• Review of randomized trials and studies on heparin treatment prior to angioplasty.
• Analysis of outcomes from thrombolytic therapy used with coronary angioplasty.
• Examination of emerging treatments including thrombin inhibitors and antiplatelet agents.

Main Results:

• Heparin pretreatment in four studies reduced abrupt vessel closure from 8-33% to 0-6%.
• No controlled trials currently exist for heparin pretreatment efficacy.
• Non-fibrin-specific plasminogen activators appear preferable when thrombolytic therapy is used with angioplasty.

Conclusions:

• Heparin plays a crucial role in managing unstable angina, particularly when preceding angioplasty.
• Thrombolytic therapy's role requires further investigation, with non-fibrin-specific agents showing promise.
• Future research focuses on novel anticoagulants and antiplatelet agents for acute ischemic syndromes.